Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCOV Phase 1 in Healthy Adults
NCT04818801Phase 1Completed
- Sponsor
- Recbio
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ReCOV with Placebo (2 arms). Primary endpoints: Number of Participants with solicited local and systemic adverse events, Number of Participants with unsolicited adverse events after each dose and 3 more. Started Jun 2021; status: completed.
02
Drugs
ReCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04818801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818801.